VIRIDIAN THERAPEUTICS INC
VRDNNASDAQπ #1488 by market capEarnings Feb 24 Β· PostUS Equity
$29.96βΌ $1.48 (β4.71%)
Market closed Β· at closeTrack VRDN
Get earnings, price moves & breaking news on Telegram
24hβΌ 4.7%
7dβΌ 2.9%
14dβ² 5.2%
30dβ² 34.0%
ytdβΌ 3.8%
1yβΌ 1.2%
π¦Market Cap
$3.40B
Small Cap
πRevenue Growth (YoY)
23359.9%
High Growth
πGross Margin
93.0%
High
π΅FCF Margin
-1305.4%
Thin
βοΈP/S Ratio
129.3x
Expensive
Otter Score
76
Strong
Trading Snapshot
- Day Range
- $29.88 β $31.75
- 52-Week Range
- $13.18 β $34.29
- Volume (shares)
- 1,747,930
- Avg Volume (shares)
- β
- Shares Outstanding
- 113.6M
- Next Earnings
- 2027-02-24
Fundamentals Snapshot
- Annual Revenue
- $71M
- Last Q Revenue
- $26M
- P/E Ratio
- -7.7
- P/S Ratio
- 129.3x
- EPS (TTM)
- $-4.00
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +5.9%
VIRIDIAN THERAPEUTICS INC
VRDNFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$71Mβ² +23359.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%β² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$363Mβ² +21.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$277Mβ² +18.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
84.8Mβ² +5.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$162Mβ² +$83M YoY
About VIRIDIAN THERAPEUTICS INC
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)πQualityβ
β
β
β
β
πGrowthβ
β
β
β
β
βοΈValuationβ
β
β
β
β
β‘Momentumβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Strong
76/100
Analyst Ratings
βConsensus
Buy
23 analysts
Strong Buy8
Buy14
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026
Latest News & Updates
News unavailable.